News
Eric Green, M.D., Ph.D., formerly the NHGRI director, has been awarded by Fierce Pharma as a Fierce 50 Innovation Honoree. The Fierce 50 is designed to honor the 50 most influential leaders and organizations shaping the future of biopharma, healthcare, and life sciences. The Fierce editorial team
The NIH Technology Transfer Program was honored with its record 7th “Deal of Distinction Award” at the 2025 Licensing Executives Society Annual Meeting. This award was given to NIH and its licensee Bavarian Nordic for the deal that led to the new chikungunya virus vaccine Vimkunya ®. Vimkunya
NIH inventors have developed the first pharmacologic option for developmental stuttering, which is currently only managed by speech therapy, but addresses a $3 billion underserved global market. This technology uses small-molecule iron chelators – drugs that bind and remove excess iron – for the
Broad access to the fruits of NIH’s investments—whether in the form of data, results, or products—drives innovation. To advance this aim, NIH is launching a new policy to improve access to medical products developed from NIH-owned inventions. This policy emphasizes the importance of proactive